c-Src (T341M)
Sign in to save this workspaceSRC · Variant type: point · HGVS: p.T341M
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Entrectinib | 99.9% | 0.1% | 93.69 |
| 2 | Repotrectinib | 99.4% | 0.6% | 84.21 |
| 3 | Pralsetinib | 99.3% | 0.7% | 93.43 |
| 4 | Crizotinib | 98.6% | 1.4% | 91.39 |
| 5 | Gilteritinib | 98.3% | 1.7% | 88.97 |
| 6 | Sunitinib | 97.5% | 2.5% | 91.73 |
| 7 | Brigatinib | 96.9% | 3.1% | 82.96 |
| 8 | Pacritinib | 96.6% | 3.4% | 88.64 |
| 9 | Defactinib | 95.7% | 4.3% | 92.68 |
| 10 | Fedratinib | 92.4% | 7.6% | 96.21 |
| 11 | Alpelisib | 92.0% | 8.0% | 97.22 |
| 12 | Selpercatinib | 91.1% | 8.9% | 96.72 |
| 13 | Bosutinib | 90.8% | 9.3% | 87.22 |
| 14 | Lorlatinib | 89.2% | 10.8% | 97.24 |
| 15 | Fostamatinib | 88.2% | 11.8% | 96.74 |
| 16 | Axitinib | 80.1% | 19.9% | 93.23 |
| 17 | Tenalisib | 77.6% | 22.4% | 97.98 |
| 18 | Nintedanib | 76.3% | 23.7% | 90.23 |
| 19 | Ponatinib | 61.4% | 38.6% | 78.23 |
| 20 | Deucravacitinib | 52.3% | 47.7% | 98.99 |
| 21 | Neratinib | 50.2% | 49.8% | 93.18 |
| 22 | Dasatinib | 48.9% | 51.1% | 87.97 |
| 23 | Futibatinib | 46.0% | 54.0% | 98.48 |
| 24 | Capivasertib | 41.5% | 58.5% | 96.48 |
| 25 | Upadacitinib | 40.7% | 59.3% | 97.98 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Entrectinib | 99.9% | — | — |
| Repotrectinib | 99.4% | — | — |
| Pralsetinib | 99.3% | — | — |
| Crizotinib | 98.6% | — | — |
| Gilteritinib | 98.3% | — | — |
| Sunitinib | 97.5% | — | — |
| Brigatinib | 96.9% | — | — |
| Pacritinib | 96.6% | — | — |
| Defactinib | 95.7% | — | — |
| Fedratinib | 92.4% | — | — |
| Alpelisib | 92.0% | — | — |
| Selpercatinib | 91.1% | — | — |
| Bosutinib | 90.8% | — | — |
| Lorlatinib | 89.2% | — | — |
| Fostamatinib | 88.2% | — | — |
| Axitinib | 80.1% | — | — |
| Tenalisib | 77.6% | — | — |
| Nintedanib | 76.3% | — | — |
| Ponatinib | 61.4% | — | — |
| Deucravacitinib | 52.3% | — | — |
| Neratinib | 50.2% | — | — |
| Dasatinib | 48.9% | — | — |
| Futibatinib | 46.0% | — | — |
| Capivasertib | 41.5% | — | — |
| Upadacitinib | 40.7% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.1ms